{"id":4506,"date":"2025-03-31T18:12:10","date_gmt":"2025-03-31T18:12:10","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/doxorubicin-hydrochloride-txt\/"},"modified":"2025-03-31T18:12:10","modified_gmt":"2025-03-31T18:12:10","slug":"doxorubicin-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/doxorubicin-hydrochloride-txt\/","title":{"rendered":"doxorubicin hydrochloride.txt"},"content":{"rendered":"

doxorubicin hydrochloride<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:Acute leukaemias Lymphomas Sarcomas Various solid tumours

DOSE IN NORMAL RENAL FUNCTION <\/H3>Varies according to local protocol

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :580<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :50\u201385<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <15<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :>20\u201330<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :30; (Liposomal: 55\u201375; Pegylated: 24\u2013231)\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis\n
  • Ciclosporin: increased risk of neurotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Reconstitute with water for injection or sodium chloride 0.9%, 10 mg in 5 mL, 50 mg in 25 mL

    Route <\/H4>IV, intra-arterial, intravesical (bladder instillation)

    Rate of Administration <\/H4>Via the tubing of a fast running intravenous infusion of sodium chloride 0.9% or glucose 5%3\u20135 minutes for the injection 24 hours for continuous infusion

    Comments<\/H4>For bladder instillation, concentration of doxorubicin in bladder should be 50 mg per 50 mL. To avoid undue dilution in urine, the patient should be instructed not to drink any fluid in the 12 hours prior to instillation. This should limit urine production to approximately 50 mL per hour

    OTHER INFORMATION <\/H4>A cumulative dose of 450\u2013550 mg\/m 2 should only be exceeded with extreme caution. Above this level, the risk of irreversible congestive cardiac failure increases greatly. Patients with impaired hepatic function have prolonged and elevated plasma concentrations of both the drug and its metabolites. Dose reduction is requiredLiposomal preparations available: up to 90 mg in 250 mL glucose 5%; if greater than 90 mg dilute in 500 mL glucose 5%Mainly metabolised in the liver. Rapidly cleared from plasma and slowly excreted in the urine and bile (50% of drug recoverable in the bile or faeces in 7 days)
    \n","protected":false},"excerpt":{"rendered":"

    doxorubicin hydrochloride CLINICAL USE Antineoplastic agent:Acute leukaemias Lymphomas Sarcomas Various<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4506","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4506"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4506\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}